Clinical Trial Update: Clinical Validation of the RENISCHEM L-FABP POC Assay

View source ↗

Summary

The document reports an ongoing clinical validation study for the RENISCHEM L-FABP point-of-care assay by Hikari Dx, Inc. The study aims to validate the test fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy
• Kidney Injury

Snippet

Sponsor: Hikari Dx, Inc. | Conditions: Acute Kidney Injury, Contrast-induced Nephropathy | Status: ACTIVE_NOT_RECRUITING